

# **EXHIBIT D**

-----Original Message-----

From: Calder, Courtney [mailto:CalderC@cdcr.fda.gov]  
Sent: Tuesday, November 22, 2005 9:35 AM  
To: 'Patel, Manini'  
Cc: 'Evertsz, Mary Ann'; 'Phelan, Kevin (New York)'  
Subject: RE: : Neurontin clarification by phone request

Hi Mary Ann,  
Please proceed with the minor labeling changes pertaining to suicide-  
related events.  
Thank you, Courtney

\*\*\*\*\*

Courtney R. Calder, Pharm.D., LT. USPHS  
Regulatory Project Manager  
Division of Neurology Products, HFD-120  
Center For Drug Evaluation and Research, FDA  
Office of Drug Evaluation I  
Ph: (301) 796-1050  
Fax: (301) 796-9842  
Email: calderc@cdcr.fda.gov